WO2007145993A3 - Modified compositions and methods for enhancing brain function - Google Patents

Modified compositions and methods for enhancing brain function Download PDF

Info

Publication number
WO2007145993A3
WO2007145993A3 PCT/US2007/013316 US2007013316W WO2007145993A3 WO 2007145993 A3 WO2007145993 A3 WO 2007145993A3 US 2007013316 W US2007013316 W US 2007013316W WO 2007145993 A3 WO2007145993 A3 WO 2007145993A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
brain function
modified compositions
compositions
enhancing brain
Prior art date
Application number
PCT/US2007/013316
Other languages
French (fr)
Other versions
WO2007145993B1 (en
WO2007145993A2 (en
Inventor
Josh Reynolds
Original Assignee
Brite Age
Josh Reynolds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brite Age, Josh Reynolds filed Critical Brite Age
Publication of WO2007145993A2 publication Critical patent/WO2007145993A2/en
Publication of WO2007145993A3 publication Critical patent/WO2007145993A3/en
Publication of WO2007145993B1 publication Critical patent/WO2007145993B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines

Abstract

Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Clinical studies have proven that contemplated compositions achieve specific improvements in cognition using a modified nootropic formulation having six active ingredients at or near threshold active dosages. Most preferably, the active ingredients are huperzine A, vinpocetine, acetyl-L-carnitine, alpha lipoic acid, rhodiola, and biotin at typically less than 2300 mg per daily dosage.
PCT/US2007/013316 2006-06-05 2007-06-05 Modified compositions and methods for enhancing brain function WO2007145993A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80394306P 2006-06-05 2006-06-05
US60/803,943 2006-06-05
US82020106P 2006-07-24 2006-07-24
US60/820,201 2006-07-24

Publications (3)

Publication Number Publication Date
WO2007145993A2 WO2007145993A2 (en) 2007-12-21
WO2007145993A3 true WO2007145993A3 (en) 2008-08-14
WO2007145993B1 WO2007145993B1 (en) 2008-09-25

Family

ID=38832348

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/013316 WO2007145993A2 (en) 2006-06-05 2007-06-05 Modified compositions and methods for enhancing brain function
PCT/US2007/013376 WO2008002382A1 (en) 2006-06-05 2007-06-06 Compositions and methods for enhancing brain function

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013376 WO2008002382A1 (en) 2006-06-05 2007-06-06 Compositions and methods for enhancing brain function

Country Status (1)

Country Link
WO (2) WO2007145993A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103539A2 (en) 2009-03-09 2010-09-16 Dinesh Shantilal Patel Sustained release oral formulation of vinpocetine
WO2011029176A1 (en) * 2009-09-14 2011-03-17 Michael Scott Buckley Concentration and mental performance amplifying formulation
AU2014235034A1 (en) * 2013-03-15 2015-10-01 Buck Institute For Research On Aging Improved cognitive supplements

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335361B1 (en) * 1999-11-03 2002-01-01 Juvenon Inc. Method of treating benign forgetfulness
US20040198754A1 (en) * 2003-03-14 2004-10-07 Pro-Health, Inc. Composition and method for appetite and craving suppression and mood enhancement
US20050053904A1 (en) * 2003-08-13 2005-03-10 Jennifer Shephard System and method for on-site cognitive efficacy assessment
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335361B1 (en) * 1999-11-03 2002-01-01 Juvenon Inc. Method of treating benign forgetfulness
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
US20040198754A1 (en) * 2003-03-14 2004-10-07 Pro-Health, Inc. Composition and method for appetite and craving suppression and mood enhancement
US20050053904A1 (en) * 2003-08-13 2005-03-10 Jennifer Shephard System and method for on-site cognitive efficacy assessment

Also Published As

Publication number Publication date
WO2007145993B1 (en) 2008-09-25
WO2008002382A1 (en) 2008-01-03
WO2007145993A2 (en) 2007-12-21
WO2008002382B1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
CA3094580A1 (en) Oral formulations of cytidine analogs and methods of use thereof
CA2563058C (en) Supportive treatment of liver disease
EP1834637A4 (en) Preventive/therapeutic composition for free radical disease
BR0214343A (en) 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20076219L (en) Pharmaceutical formulation with apomorphine for buccal administration
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2010033236A3 (en) Methods and compositions for treating bacterial infections by inhibiting quorum sensing
WO2007056264A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
WO2008030830A3 (en) Sustained-release composition and method of use thereof
EP1177791A3 (en) Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
NO20054216L (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
EP2275110A3 (en) Cladribine regimen for treating Multiple Sclerosis
WO2006138317A3 (en) Dosage regimen for prasugrel
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
EP1778209B8 (en) Methods and compositions for oral delivery of fts
WO2004032873A3 (en) Therapeutic combination of carnitine and antioxidant polyphenols
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
WO2007145993A3 (en) Modified compositions and methods for enhancing brain function
WO2006071564A3 (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07809354

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07809354

Country of ref document: EP

Kind code of ref document: A2